Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05270824 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 8, 2022 (before its estimated March 1, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Focusing on the clinical question of whether patients with advanced gastric cancer can benefit from immunotherapy, this project intends to detect the degree of CD8+ tumor-infiltrating lymphocyte infiltration in patients with advanced gastric cancer before and after receiving neoadjuvant combined immunotherapy and neoadjuvant therapy alone. To explore the evolving nature of tumor immune response before and after neoadjuvant therapy for gastric cancer, and quantitatively present it through chemical immunohistochemical techniques to achieve a more accurate diagnosis and treatment and improve the long-term efficacy of patients.
Trial Details
NCT Number NCT05270824
Lead Sponsor Fujian Medical University
Conditions
(from sponsor)		 Advanced Gastric Carcinoma, CD8+ Tumor Infiltrating Lymphocytes, Neoadjuvant Immunotherapy
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov